Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox in Erythematotelangiectatic Rosacea
NCT06331533Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2022
- Primary completion
- May 2023
- Countries
- 1
- Sponsor
- Istanbul Education Research Hospital
- Modality
- Recombinant Proteins and Enzymes
- Conditions
- rosacea
01
Overview
Phase 4, randomised, double-blind trial in rosacea comparing Botulinum toxin A with Placebo (2 arms). Primary endpoints: Clinician's Erythema Assessment at 1 month, Erythema Index at 1 month and 3 more. Started Nov 2022; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Botulinum toxin A
Placebo
03
Who it enrols
Adults aged 18-60 with erythematotelangiectatic rosacea, excluding those with recent medication use, prior Botox injections, or history of neuromuscular/autoimmune diseases.
04
Endpoints
Primary
Clinician's Erythema Assessment
Erythema Index
Melanin Index
Dermatoscopic Erythema Analysis
Patient Self-Assessment
Secondary
Vascular Structure Analysis
Beyond the preview
Go deeper on NCT06331533.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331533.